07 Jan 2001

Doxymono® 100 (Doxymono® 100/-200 Tabletten) - Deutschland

Updated: 07 Jan 2001

Doxymono® 100 | -200

Infektionen, verursacht durch Doxycyclin-empfindl. Krankheitserreger, z. B. d. Atemwege u. d. HNO-Bereiches, akute Schübe chron. Bronchitis, Sinusitis, Otitis media, Pneumonie durch Mykoplasmen, Rickettsien od. Chlamydien. Infekt. d. Urogenitaltraktes, Urethritis durch Chlamydien u. Ureaplasma urealyticum, akute Prostatitis, unkomplizierte Gonorrhoe (insb. b. gleichz. Chlamydieninf.). Infekt. d. weibl. Geschlechtsorgane, Syphilis b. Penicillin-Allergie, Harnwegsinfekt. (nur b. nachgewiesener Empf. d. Erregers). Infekt. d. Magen-Darm-Traktes, Cholera, Yersinien- od. Campylobacter-Infekt. Shigellen-Inf. b. Nachweis d. Empf. Malabsorptionssyndrome wie tropische Sprue u. Morbus Whipple. Ambulante Ther. v. Gallenwegsinfekt. Hauterkr. auch infizierte schwere Formen d. Akne vulg. u. Rosacea, Chlamydien-Konjunktivitis u. Trachom, Borreliosen wie Erythema chronicum migrans u. Lyme-Disease, seltene Infektionen, wie Bartonellose, Brucellose, Listeriose, Ornithose, Rickettsiose, Melioidose, Pest, Granuloma inguinale

Doxymono® 100 Description, Presentation and Dosage

Doxymono® 100 Description

Doxymono® 100 Drug Class Description

Doxycyclin

Doxymono® 100 Drug Description

1 teilbare Tbl. enth.: Doxycyclin 1H2O 104,1 mg/208,2 mg (entspr. 100 mg/200 mg Doxycyclin).

Doxymono® 100 Generic Name

Doxymono® 100/-200 Tabletten

Doxymono® 100 Presentation

Doxymono® 100 Presentation

Doxymono® 100/-200

Doxymono® 100 Manufacturer

betapharm

Related Learning Zones

Bedwetting Knowledge Centre and
Interactive Case Studies

Bedwetting Knowledge Centre and </br>Interactive Case Studies

The Bedwetting Knowledge Centre, independently reviewed for clinical accuracy by Søren Rittig, MD, DMSc, aims to equip healthcare professionals with the information and guidance they need to effectively diagnose, treat and refer patients with nocturnal enuresis. This mobile-optimised resource contains disease awareness information, best practice guidelines and interactive case studies: ‘Case Studies in Urology: Best Practice Management of Bedwetting’.

Cystic Fibrosis Knowledge Centre

Cystic Fibrosis Knowledge Centre

Cystic fibrosis (CF) is a genetic condition caused by a defect in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel. The Cystic Fibrosis Knowledge Centre provides healthcare professionals with access to disease awareness information, emerging and established treatment options and current best practice based on recently updated guidelines by the European Cystic Fibrosis Society (ECFS). A resources section contains external links to upcoming medical conferences and patient support groups.

This resource is developed by EPG Health Media for epgonline.org, supported by an independent educational grant from Vertex.

Doxymono® 100 Dosage

Doxymono® 100 Adult Dosage

mikrokristalline Cellulose, Magnesiumstearat, Poly(O-carboxymethyl)stärke-Natriumsalz, Povidon, hydriertes Rizinusöl, hochdisp. Siliciumdioxid.

Doxymono® 100 Precautions, Reactions and Contraindications

Doxymono® 100 Special Precautions

Doxymono® 100 Special Precautions

T 15 a, b

Doxymono® 100 Adverse Reactions

Doxymono® 100 Adverse Reactions

T 15

Related Drugs - Infectious Diseases

Back to top